menu
    • menu

    Company profile for Dizal Pharmaceutical

    NEW Drugs in Dev: 9
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dizal Pharmaceutical is a global, science-oriented pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines. Dizal has built world's leading position in the translational science, new-drug molecular design and screening technology platform. It has accumulated extensive experience in the development of innovative therapies for the treatment of cancer, immunological diseases and ch...
    Dizal Pharmaceutical is a global, science-oriented pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines. Dizal has built world's leading position in the translational science, new-drug molecular design and screening technology platform. It has accumulated extensive experience in the development of innovative therapies for the treatment of cancer, immunological diseases and chronic kidney diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dizal PharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, Shanghai, China, 2...
    Telephone
    Telephone
    +86-21-61097800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.dizalpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dizal-pharma/life/48887300-daea-470e-8420-5be14b984685/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dizal Presents 4th-Gen EGFR TKI DZD6008 + Golidocitinib Data
    Dizal Presents 4th-Gen EGFR TKI DZD6008 + Golidocitinib Data

    31 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-presents-positive-nsclc-data-for-fourth-generation-egfr-tki-dzd6008-and-golidocitinib-in-combination-with-anti-pd-1-at-asco-2026-302786360.html

    PR NEWSWIRE
    31 May 2026
    Share Share
    Sunvozertinib Beats Chemo in Phase 3 EGFR Exon 20 NSCLC Trial
    Sunvozertinib Beats Chemo in Phase 3 EGFR Exon 20 NSCLC Trial

    29 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-announces-phase-3-wu-kong28-results-zegfrovy-sunvozertinib-outperforms-platinum-doublet-chemotherapy-in-first-line-egfr-exon-20-insertion-mutation-positive-non-small-cell-lung-cancer-302785656.html

    PR NEWSWIRE
    29 May 2026
    Share Share
    Dizal's Sunvozertinib NDA Gets Priority Review in China
    Dizal's Sunvozertinib NDA Gets Priority Review in China

    27 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizals-zegfrovy-sunvozertinib-new-drug-application-accepted-and-granted-priority-review-by-china-national-medical-products-administration-for-first-line-treatment-of-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-302783017.html

    PR NEWSWIRE
    27 May 2026
    Share Share
    Dizal to Report NSCLC Portfolio Progress at ASCO 2026
    Dizal to Report NSCLC Portfolio Progress at ASCO 2026

    21 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-to-report-key-progress-in-its-nsclc-portfolio-with-two-oral-presentations-and-a-poster-during-asco-2026-302749044.html

    PR NEWSWIRE
    21 Apr 2026
    Share Share
    Dizal's ZEGFROVY Demonstrates Strong Antitumor Activity
    Dizal's ZEGFROVY Demonstrates Strong Antitumor Activity

    27 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizals-zegfrovy-sunvozertinib-shows-profound-antitumor-activity-as-first-line-treatment-in-advanced-nsclc-patients-with-pacc-or-other-uncommon-mutations-at-elcc-2026-302727267.html

    PR NEWSWIRE
    27 Mar 2026
    Share Share
    Dizal's Zegfrovy Adds More Pressure To J&J's Rybrevant
    Dizal's Zegfrovy Adds More Pressure To J&J's Rybrevant

    23 Mar 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/dizal-zegfrovy-clinches-landmark-phase-3-win-first-line-egfr-exon-20-nsclc-challenging-jj

    FIERCE PHARMA
    23 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search